

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10508738	
	Filing Date		2005-05-18	
	First Named Inventor	Eric Simard		
	Art Unit	1643		
	Examiner Name	Meera Natarajan		
	Attorney Docket Number	24913/04004		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10508738
Filing Date		2005-05-18
First Named Inventor	Eric Simard	
Art Unit		1643
Examiner Name	Meera Natarajan	
Attorney Docket Number		24913/04004

/M.N./	1	International Search Report from PCT/CA03/00434, mailed September 24, 2003, 5 pgs.	<input type="checkbox"/>
/M.N./	2	Byrd-Leifer, et al., "The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol", Eur. J. Immunol. 2001, 31, pp. 2448-2457.	<input type="checkbox"/>
/M.N./	3	Emens et al., "Chemotherapy: Friend or foe to cancer vaccines?", Current Opinion in Molecular Therapeutics, 2001 3 (1), pp. 77-84.	<input type="checkbox"/>
/M.N./	4	Lee et al., "Identification of Tumor-Specific Paclitaxel (Taxol)-Responsive Regulatory Elements in the Interleukin-8 Promoter", Molecular and Cellular Biology, Sept. 1997, pp. 5097-5105, Vol. 17, No. 9.	<input type="checkbox"/>
/M.N./	5	Machiels et al., "Cyclophosphamide, Doxorubicin, and Paclitaxel Enhance the Antitumor Immune Response of Granulocyte/Macrophage-Colony Stimulating Factor-secreting Whole-Cell Vaccines in HER-2/neu Tolerized Mice", Cancer Research, 61, pp. 3689-3697, May 1, 2001.	<input type="checkbox"/>
/M.N./	6	Nigam et al., "Immunomodulatory properties of antineoplastic drugs administered in conjunction with GM-CSF-secreting cancer cell vaccines", International Journal of Oncology, 12: pp. 161-170, 1998.	<input type="checkbox"/>
/M.N./	7	Perera et al., "Paclitaxel (Taxol)-Induced NF-kB Translocation in Murine Macrophages", Infection and Immunity, Mar. 1996, pp. 878-884, Vol. 64.	<input type="checkbox"/>
/M.N./	8	Radcliff, et al., "Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy", British Journal of Haematology, 2002, 119, pp. 204-211.	<input type="checkbox"/>
/M.N./	9	Reece et al., "Use of anti-idiotypic (ID) antibody (AB) vaccine 11D10 (TRIAB) in patients (PTS) with metastatic breast cancer (MBC) undergoing autologous stem cell transplantation (ASCT)", Blood, vol. 96, no. 11, part 1, November 16, 2000, pg. 844a, 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, Dec. 1-5, 2000, ABSTRACT.	<input type="checkbox"/>
/M.N./	10	Zagozdzon et al., "Immunomodulation by anticancer chemotherapy: More is not always better (Review)", International Journal of Oncology, 18, pp. 417-424, 2001.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10508738
Filing Date	2005-05-18
First Named Inventor	Eric Simard
Art Unit	1643
Examiner Name	Meera Natarajan
Attorney Docket Number	24913/04004

**EXAMINER SIGNATURE**

Examiner Signature	/Meera Natarajan/	Date Considered	12/04/2008
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.